PT Kalbe Farma Tbk (PTKFY)
OTHER OTC:PTKFY
Top Page
PT Kalbe Farma Tbk
(OTC:PTKFY)
Select Model
Select Model
Rating:67Neutral
Price Target:
$15.50
▲(5.73% Upside)
Action:ReiteratedDate:12/19/25
PTKFY's overall score of 67 reflects a stable but cautious outlook, driven primarily by financial performance (score: 67, weight: 0.5) with a strong balance sheet offset by revenue and cash flow declines. Valuation (score: 75, weight: 0.2) supports the score with a reasonable P/E and attractive dividend yield, while technical analysis (score: 60, weight: 0.3) indicates mixed momentum. Growth challenges remain the key risk.
Positive Factors
Strong Balance Sheet
A strong balance sheet with minimal leverage enhances financial stability and flexibility, allowing the company to invest in growth opportunities without significant financial risk.
Negative Factors
Declining Revenue Growth
A significant decline in revenue growth can indicate challenges in market expansion or product demand, potentially impacting future earnings and market position.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Balance Sheet
A strong balance sheet with minimal leverage enhances financial stability and flexibility, allowing the company to invest in growth opportunities without significant financial risk.
Read all positive factors
PT Kalbe Farma Tbk (PTKFY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.65B
Dividend Yield3.33%
Average Volume (3M)154.00
Price to Earnings (P/E)20.5
Beta (1Y)0.55
Revenue Growth3.32%
EPS Growth11.04%
CountryUS
Employees12,841
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)N/A
Shares Outstanding234,066,960
10 Day Avg. Volume0
30 Day Avg. Volume154
Financial Highlights & Ratios
PEG Ratio1.37
Price to Book (P/B)3.38
Price to Sales (P/S)2.36
P/FCF Ratio21.81
Enterprise Value/Market Cap15.11K
Enterprise Value/Revenue1.16
Enterprise Value/Gross Profit2.88
Enterprise Value/Ebitda7.78
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PT Kalbe Farma Tbk Business Overview & Revenue Model
Company Description
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribu...
How the Company Makes Money
PT Kalbe Farma generates revenue through multiple key streams, including the sale of prescription pharmaceuticals, over-the-counter medications, and nutritional products. The company's prescription drug segment is particularly important, contribut...
PT Kalbe Farma Tbk Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
80
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.42T | 32.63T | 30.45T | 28.93T | 26.26T | 23.11T |
| Gross Profit | 13.88T | 12.96T | 11.82T | 11.70T | 11.28T | 10.25T |
| EBITDA | 5.14T | 4.61T | 4.02T | 5.25T | 4.87T | 4.35T |
| Net Income | 3.50T | 3.24T | 2.77T | 3.38T | 3.18T | 2.73T |
Balance Sheet | ||||||
| Total Assets | 29.95T | 29.43T | 27.06T | 27.24T | 25.67T | 22.56T |
| Cash, Cash Equivalents and Short-Term Investments | 4.18T | 4.87T | 3.40T | 4.10T | 6.48T | 5.40T |
| Total Debt | 518.68B | 559.22B | 618.54B | 1.17T | 626.16B | 1.16T |
| Total Liabilities | 5.27T | 4.84T | 3.94T | 5.14T | 4.40T | 4.29T |
| Stockholders Equity | 22.86T | 22.79T | 21.42T | 20.39T | 19.58T | 17.41T |
Cash Flow | ||||||
| Free Cash Flow | 2.67T | 3.53T | 1.73T | 2.90T | 1.83T | 3.10T |
| Operating Cash Flow | 3.47T | 4.79T | 2.91T | 3.77T | 2.83T | 4.21T |
| Investing Cash Flow | -560.71B | -1.25T | -1.14T | -1.37T | -1.06T | -951.22B |
| Financing Cash Flow | -3.12T | -2.09T | -2.44T | -2.41T | -745.18B | -1.10T |
PT Kalbe Farma Tbk Technical Analysis
Negative
14.66
Price Trends
12.75
Negative
13.64
Negative
14.93
Negative
Market Momentum
-0.36
Negative
32.99
Neutral
56.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PTKFY, the sentiment is Negative. The current price of 14.66 is above the 20-day moving average (MA) of 11.78, above the 50-day MA of 12.75, and below the 200-day MA of 14.93, indicating a bearish trend. The MACD of -0.36 indicates Negative momentum. The RSI at 32.99 is Neutral, neither overbought nor oversold. The STOCH value of 56.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PTKFY.
PT Kalbe Farma Tbk Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $2.65B | 20.48 | 15.61% | 3.33% | 3.32% | 11.04% | |
52 Neutral | $1.52B | 9.95 | 25.50% | 4.80% | -1.69% | -61.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $6.20B | 14.03 | 7.56% | 1.56% | 9.45% | 167.00% | |
45 Neutral | $45.18M | ― | -55.19% | ― | ― | ― | |
43 Neutral | $35.16M | -0.22 | 435.85% | ― | -8.12% | ― |
* Healthcare Sector Average
PTKFY
PT Kalbe Farma Tbk
11.32
-2.19
-16.23%
GRFS
Grifols SA
7.49
0.47
6.70%
SRXH
SRx Health Solutions
0.12
-1.60
-93.20%
SCLX
Scilex Holding Company
6.41
-2.29
-26.32%
OGN
Organon
5.84
-8.91
-60.40%
CTOR
Citius Oncology
0.51
-0.42
-45.05%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.